Given the heterogeneity in study populations and the predominance of post hoc analyses, further prospective research is essential to clarify these mechanisms and to evaluate whether personalized, sex-specific approaches to GLP-1 RA therapy could improve obesity treatment outcomes
I feel amazing...- Rachel, Semaglutide Patient THE BENEFITS OF GLP-1 Suppresses the Appetite Weight-Loss Quiets Food Noise Reduces Insulin Resistance BEYOND WEIGHT-LOSS: CLINICAL STUDIES The GLP-1 class of medications that semaglutide belongs to has been on the market for over 20 years and is highly studied
McCarty concluded
One promising avenue is the use of incretin medications, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, which have shown potential in preclinical and clinical studies (Fink-Jensen and Vilsbll 2016
[2] Additionally, GLP-1 agonists have been shown to reduce markers of systemic inflammation, including C-reactive protein (CRP), in patients with type 2 diabetes and cardiovascular disease, though these reductions are often modest
It is important to hold this information loosely, as the space is evolving rapidly and additional approvals are likely to follow
